• Citer

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

par Trøseid, Marius;Hites, Maya
Référence Critical care, 27, 1, 9
Publication A Paraître, 2023-12-31

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Auteur:	Trøseid, Marius; Hites, Maya
Informations sur la publication:	Critical care, 27, 1, 9
Statut de publication:	A Paraître, 2023-12-31
Sujet CREF:	Soins intensifs réanimation
Mots-clés:	Baricitinib
	COVID-19
	Safety
	Vaccination
MeSH keywords:	Humans
	Adult
	Male
	Middle Aged
	Female
	COVID-19
	SARS-CoV-2
	RNA, Viral
	COVID-19 Drug Treatment
	Double-Blind Method
Note générale:	SCOPUS: ar.j
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1364-8535
	info:doi/10.1186/s13054-022-04205-8
	info:pii/10.1186/s13054-022-04205-8
	info:scp/85146105672
	info:pmid/36627655
	PMC9830601